| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Hydroxygenkwanin (7-O-methylluteolin) inhibits the growth of C6 glioma cells in a dose-dependent manner [1]. Flow cytometry indicates that hydrogen kwanin decreases the ability to form colonies and mote cells and causes cell cycle arrest. Hydroxygenkwanin causes cell cycle arrest and starts the intrinsic apoptotic pathway by activating p21 [2].
|
|---|---|
| References |
[1]. Wang Y, et al. Synergistic anti-glioma effect of Hydroxygenkwanin and Apigenin in vitro. Chem Biol Interact. 2013 Nov 25;206(2):346-55.
[2]. Huang YC, et al. Anticancer Effect and Mechanism of Hydroxygenkwanin in Oral Squamous Cell Carcinoma. Front Oncol. 2019 Sep 18;9:911. |
| Molecular Formula |
C16H12O6
|
|---|---|
| Molecular Weight |
300.2629
|
| Exact Mass |
300.06
|
| Elemental Analysis |
C, 64.00; H, 4.03; O, 31.97
|
| CAS # |
20243-59-8
|
| Appearance |
Solid powder
|
| SMILES |
COC1=CC(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O
|
| InChi Key |
RRRSSAVLTCVNIQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O6/c1-21-9-5-12(19)16-13(20)7-14(22-15(16)6-9)8-2-3-10(17)11(18)4-8/h2-7,17-19H,1H3
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxychromen-4-one
|
| Synonyms |
HGK; 3'Hydroxygenkwanin; 3' Hydroxygenkwanin; 3'-Hydroxygenkwanin; Luteolin 7-methyl ether; Luteolin 7 methyl ether; 7-O-Methylluteolin; 7OMethylluteolin; Luteolin 7methyl ether; 7 O Methylluteolin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~33.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.77 mg/mL (2.56 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | |
| 5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
